Wall Street traders sent stocks lower in the run-up to the Federal Reserve decision, with concerns about high valuations ...

Shares of Sarepta surged Tuesday, a day after the FDA said the company could lift a voluntary pause on shipments of its Elevidys drug, which had been linked to three patient deaths this year. The ...

Shares of Sarepta Therapeutics surged Tuesday morning after the company said it had been informed by the Food and Drug Administration that it could resume shipping a drug it paused sales of last week.

Sarepta Therapeutics ( NASDAQ: SRPT) was upgraded to Neutral from Underweight at J.P. Morgan as it sees FDA's Elevidys hold removal recommendation in ambulatory patients as a clear win.

A rally in stocks toward all-time highs lost steam as Wall Street traders waded through economic data and corporate earnings ...

This regulatory relief, combined with several other compelling catalysts, creates a pathway for the stock to potentially ...

What's next for the stock market? Dow and Nasdaq futures rise as investors await Big Tech earnings and interest rate decision by the Fed.

Investor attention is shifting from geopolitics to corporate fundamentals as earnings begin to eclipse tariffs as the primary market catalyst, according to Barclays (LON:BARC).

Sarepta Therapeutics shares surged more than 30% before the bell on Tuesday, as analysts said the resumption of U.S. shipments for its muscular gene therapy partially removes financial headwinds and ...

September S&P 500 E-Mini futures (ESU25) are trending up +0.24% this morning, extending yesterday’s gains, while investors ...

View the latest Sarepta Therapeutics Inc. (SRPT) stock price, news, historical charts, analyst ratings and financial information from WSJ.

A timeline of key developments surrounding Sarepta Therapeutics' Duchenne muscular dystrophy drug Elevidys, and the potential ...